EUVIMEDEUVIMED entdecken
Open Access

Hybrid nanoparticle–mediated simultaneous ROS scavenging and STING activation improve the antitumor immunity of in situ vaccines

Jianing Li iD, Tianze Wu, Weidong Wang iD, Yimin Gong iD, Mingzhu Lu, Mengmeng Zhang, Wanyue Lu, Yaming Zhou iD, Yannan Yang iD

Science Advances · 2024

DOI: 10.1126/sciadv.adn3002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Jianing Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Department of Chemistry, Fudan University, Shanghai 200433, China. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Nanoparticles, Cancer Vaccines, Dendritic Cells. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In situ vaccine (ISV) is a versatile and personalized local immunotherapeutic strategy. However, the compromised viability and function of dendritic cells (DCs) in a tumor microenvironment (TME) largely limit the therapeutic efficacy. We designed a hybrid nanoparticle–based ISV, which accomplished superior cancer immunotherapy via simultaneously scavenging reactive oxygen species (ROS) and activating the stimulator of interferon genes (STING) pathway in DCs. This ISV was constructed by encapsulating a chemodrug, SN38, into diselenide bond–bridged organosilica nanoparticles, followed by coating with a Mn 2+ -based metal phenolic network. We show that this ISV can activate the STING pathway through Mn 2+ and SN38 comediated signaling and simultaneously scavenge preexisting H 2 O 2 in the TME and Mn 2+ -catalyzed •OH by leveraging the antioxidant property of diselenide and polyphenol. This ISV effectively activated DCs and protected them from oxidative damage, leading to remarkable downstream T cell activation and systemic antitumor immunity. This work highlights a nanoparticle design that manipulates DCs in the TME for improving the ISV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reactive Oxygen SpeciesNanoparticlesCancer VaccinesDendritic CellsTumor MicroenvironmentMembrane ProteinsAnimalsMiceHumansNeoplasmsCell Line, TumorImmunotherapyFree Radical ScavengersSTING Protein

Substanzen

Reactive Oxygen SpeciesCancer VaccinesMembrane ProteinsFree Radical ScavengersSting1 protein, mouseSTING Protein

Autor:innen und Institutionen

  • Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Department of Chemistry, Fudan University, Shanghai 200433, China.
  • Institute of Optoelectronics, Fudan University, Shanghai 200433, China.
  • South Australian immunoGENomics Cancer Institute, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia 5005, Australia.

ORCID-Profile: Jianing Li, Weidong Wang, Yimin Gong, Yaming Zhou, Yannan Yang

Zitieren

APA

Li, J., Wu, T., Wang, W., Gong, Y., Lu, M., Zhang, M., Lu, W., Zhou, Y., & Yang, Y. (2024). Hybrid nanoparticle–mediated simultaneous ROS scavenging and STING activation improve the antitumor immunity of in situ vaccines. Science Advances. https://doi.org/10.1126/sciadv.adn3002

Vancouver

Li J, Wu T, Wang W, Gong Y, Lu M, Zhang M, et al. Hybrid nanoparticle–mediated simultaneous ROS scavenging and STING activation improve the antitumor immunity of in situ vaccines. Science Advances. 2024. doi:10.1126/sciadv.adn3002

BibTeX
@article{Li2024,
  author = {Li, Jianing and Wu, Tianze and Wang, Weidong and Gong, Yimin and Lu, Mingzhu and Zhang, Mengmeng and Lu, Wanyue and Zhou, Yaming and Yang, Yannan},
  title = {Hybrid nanoparticle–mediated simultaneous ROS scavenging and STING activation improve the antitumor immunity of in situ vaccines},
  journal = {Science Advances},
  year = {2024},
  doi = {10.1126/sciadv.adn3002}
}
Kostenlos starten →